CD274 and non-small cell lung carcinoma: First-line therapies for patients with driver gene-negative metastatic NSCLC include ICI monotherapy (high PD-L1 expression) (Mok et al., 2019; Herbst et al., 2020; Papadimitrakopoulou et al., 2020; Akinboro et al., 2022), ICI + platinum-based chemotherapy (regardless of PD-L1 expression) (Reck et al., 2022), and a four-drug combination of bevacizumab and atezolizumab plus chemotherapy (Socinski et al., 2018).